Quest Partners LLC Sells 6,638 Shares of Progyny, Inc. (NASDAQ:PGNY)

Quest Partners LLC reduced its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 39.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,292 shares of the company’s stock after selling 6,638 shares during the quarter. Quest Partners LLC’s holdings in Progyny were worth $172,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. RiverPark Advisors LLC lifted its holdings in Progyny by 9.6% during the second quarter. RiverPark Advisors LLC now owns 5,408 shares of the company’s stock worth $155,000 after acquiring an additional 474 shares during the period. Arizona State Retirement System lifted its holdings in Progyny by 2.6% during the second quarter. Arizona State Retirement System now owns 24,313 shares of the company’s stock worth $696,000 after acquiring an additional 609 shares during the period. State of New Jersey Common Pension Fund D lifted its holdings in Progyny by 1.1% during the second quarter. State of New Jersey Common Pension Fund D now owns 70,717 shares of the company’s stock worth $2,023,000 after acquiring an additional 787 shares during the period. Quarry LP lifted its holdings in Progyny by 1,900.0% during the second quarter. Quarry LP now owns 880 shares of the company’s stock worth $25,000 after acquiring an additional 836 shares during the period. Finally, Creative Planning lifted its holdings in Progyny by 13.8% during the second quarter. Creative Planning now owns 10,564 shares of the company’s stock worth $302,000 after acquiring an additional 1,283 shares during the period. 94.93% of the stock is currently owned by institutional investors.

Progyny Stock Performance

NASDAQ:PGNY opened at $15.48 on Thursday. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $42.08. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of 26.66, a PEG ratio of 1.82 and a beta of 1.44. The business’s fifty day moving average is $16.04 and its 200 day moving average is $22.40.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company had revenue of $286.63 million for the quarter, compared to the consensus estimate of $296.85 million. During the same quarter in the previous year, the firm posted $0.16 earnings per share. The business’s revenue for the quarter was up 2.0% compared to the same quarter last year. Equities analysts predict that Progyny, Inc. will post 0.58 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Leerink Partners lowered their target price on Progyny from $25.00 to $21.00 and set a “market perform” rating on the stock in a research note on Thursday, September 19th. Jefferies Financial Group lowered their target price on Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, September 19th. JPMorgan Chase & Co. lowered their target price on Progyny from $31.00 to $22.00 and set an “overweight” rating on the stock in a research note on Thursday, September 19th. Canaccord Genuity Group lowered Progyny from a “buy” rating to a “hold” rating and lowered their target price for the company from $37.00 to $24.00 in a research note on Wednesday, August 7th. Finally, Canaccord Genuity Group lowered their target price on Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a research note on Wednesday, November 13th. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $25.42.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.